|Instrument||Recommended Number of Samples||Read Length|
|NextSeq 550 System||Samples per run (high output): 16 (8 DNA + 8 RNA), 10 if DNA only, 16 if RNA only||2 × 101 bp (max recommended)|
|HiSeq 2500 System||Samples per run (rapid run): 12 (6 DNA + 6 RNA), 6 if DNA only, 12 if RNA only||2 × 101 bp (max recommended)|
|NovaSeq 6000 System||Samples per run (dual flow cell): S1: 96, S2: 96, S4: 192 (limited by index combinations)||2 x 100 bp (max recommended)|
|TruSight Tumor 170||TruSight Tumor 15||AmpliSeq for Illumina Focus Panel||AmpliSeq for Illumina Comprehensive Panel v3||AmpliSeq for Illumina Cancer Hotspot Panel v2|
|Assay Time||~2 days (Library Prep)||7 hours||5-6 hours (library prep only; doesn't include library quantification, normalization, or pooling time)||5-6 hours (library prep only; doesn't include library quantification, normalization, or pooling time)||5 hours (library prep only; doesn't include library quantification, normalization, or pooling time)|
|Cancer Type||Solid Tumor||Solid Tumor||Solid Tumor||Solid Tumor||Pan-Cancer, Solid Tumor|
|Content Specifications||Probes enrich for full coding sequences of 170 genes. Calls single nucleotide variants, small insertions, and deletions in 151 genes, amplifications in 59 genes, and fusions plus splice variants in 55 genes.||Amplifies 250 amplicons from 15 genes associated with solid tumors||DNA and RNA targets for 52 oncogenes||DNA and RNA targets for 161 oncogenes||Hotspot regions of 50 genes with known associations to cancer|
|Description||Perform comprehensive somatic variant detection research in solid tumors using variant calling information from both DNA and RNA.||Focused panel to study relevant solid tumor somatic variants in 15 genes using a simple workflow.||Somatic analysis research on 52 genes associated with solid tumor cancers.||Somatic analysis research on hotspot and full-length targets of genes associated with solid tumor cancers.||Somatic analysis research into hotspot regions of 50 cancer-related genes.|
|Hands-On Time||~10.5 hours||3.5 hours||< 1.5 hours||< 1.5 hours||< 1.5 hours|
|Input Quantity||40 ng DNA and/or RNA||20 ng||1–100 ng (10 ng recommended per pool)||1–100 ng (10 ng recommended per pool)||1–100 ng (10 ng recommended per pool)|
|Method||Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing||Amplicon Sequencing , Targeted DNA Sequencing||Amplicon Sequencing , Targeted DNA Sequencing , Targeted RNA Sequencing||Amplicon Sequencing , Targeted DNA Sequencing , Targeted RNA Sequencing||Amplicon Sequencing , Targeted DNA Sequencing|
|Multiplexing||Up to 32-plex for DNA using both index sets, up to 16-plex for RNA||1-24-plex||96 dual index combinations||96 dual index combinations||96 dual index combinations|
|Nucleic Acid Type||RNA, DNA||DNA||DNA, RNA||DNA, RNA||DNA|
|Specialized Sample Types||FFPE Tissue, Low-Input Samples||FFPE Tissue, Low-Input Samples||Blood, FFPE Tissue||Blood, FFPE Tissue||Blood, FFPE Tissue|
TruSight Tumor 170 Panel enables translational researchers to seek answers to multiple questions in one assay.Read Interview
Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.
Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.
TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.
Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.